AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35914543 — intervention group
Group type: COMPARATOR
Intervention: Dulaglutide 0.75 mg
Number of subjects: 636
Study 32208889 — intervention group
Group type: EXPERIMENTAL
Intervention: Periarticular multidrug infiltration (PMDI)
Number of subjects: 58
Study 32208889 — intervention group
Group type: COMPARATOR
Intervention: Epidural catheter
Number of subjects: 58
Study 34453416 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic tadalafil tablet (10 mg)
Number of subjects: 53
Study 34453416 — intervention group
Group type: COMPARATOR
Intervention: Marketed tadalafil tablet (10 mg)
Number of subjects: 53
Study 33785656 — intervention group
Group type: EXPERIMENTAL
Intervention: Accentuated eccentric loading (AEL)
Number of subjects: 0
Study 33785656 — intervention group
Group type: COMPARATOR
Intervention: Traditional loading (TL)
Number of subjects: 0
Study 32883351 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraviolet-cabinets (UVc) for fluorescent-alcohol-based handrubs (AHR)
Number of subjects: 242
Study 32883351 — intervention group
Group type: COMPARATOR
Intervention: Control group (visual supervision of a tutor)
Number of subjects: 242
Study 34516308 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 13885
Study 34516308 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 13885
Study 34516308 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 13885
Study 32979645 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI/bevacizumab (bev)
Number of subjects: 1187
Study 32979645 — intervention group
Group type: COMPARATOR
Intervention: Doublets (FOLFOX or FOLFIRI)/bevacizumab (bev)
Number of subjects: 1187
Study 32979645 — intervention group
Group type: EXPERIMENTAL
Intervention: Locoregional treatments (LRTs)
Number of subjects: 1187
Study 32979645 — intervention group
Group type: EXPERIMENTAL
Intervention: Locoregional treatments (LRTs) after first progression
Number of subjects: 1187
Study 34579131 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Selenite Injection (SE)
Number of subjects: 29
Study 34579131 — intervention group
Group type: COMPARATOR
Intervention: Placebo (CTRL)
Number of subjects: 29
Study 32059011 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved Water, Sanitation, and Hygiene (WASH)
Number of subjects: 1169
Study 32059011 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved Infant and Young Child Feeding (IYCF)
Number of subjects: 1169
Study 32059011 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 1169
Study 35351178 — intervention group
Group type: EXPERIMENTAL
Intervention: Early neurosurgical hematoma evacuation
Number of subjects: 300
Study 35351178 — intervention group
Group type: COMPARATOR
Intervention: Initial conservative management with the possibility of delayed secondary surgery
Number of subjects: 300
Study 32252544 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Cognitive Stimulation Therapy (iCST), 14 sessions of 45 minutes each
Number of subjects: 33
Study 32252544 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 33
Study 36152268 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-HBc level < 325 IU/ml
Number of subjects: 136
Study 36152268 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-HBc level ≥ 325 IU/ml
Number of subjects: 136
Study 36152268 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of anti-HBc < 325 IU/ml with HBsAg >3008 IU/mL
Number of subjects: 136
Study 36152268 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of anti-HBc < 325 IU/ml with HBcrAg ≥1790 U/ml
Number of subjects: 136
Study 34256459 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for pancreatic cancer with liver metastasis
Number of subjects: 0
Study 34256459 — intervention group
Group type: COMPARATOR
Intervention: Systematic chemotherapy (current standard treatment)
Number of subjects: 0
Study 33586958 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuous molecular dynamics (DMD) simulations of ovispirin-1 peptide on graphene surface
Number of subjects: 0
Study 33586958 — intervention group
Group type: EXPERIMENTAL
Intervention: DMD simulations
Number of subjects: 0
Study 33586958 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophobic graphene surface
Number of subjects: 0
Study 32702706 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise plus energy restriction (EXER)
Number of subjects: 60
Study 32702706 — intervention group
Group type: COMPARATOR
Intervention: Energy restriction only (ER)
Number of subjects: 60
Study 34137177 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous serum (AS) eye drops
Number of subjects: 63
Study 34137177 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic Serum (HS) eye drops
Number of subjects: 63
Study 34137177 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical Cord serum (CS) eye drops
Number of subjects: 63
Study 34137177 — intervention group
Group type: COMPARATOR
Intervention: Visual acuity
Number of subjects: 63
Study 34137177 — intervention group
Group type: COMPARATOR
Intervention: Schirmer test
Number of subjects: 63
Study 34137177 — intervention group
Group type: COMPARATOR
Intervention: Breakup time (BUT)
Number of subjects: 63
Study 34137177 — intervention group
Group type: COMPARATOR
Intervention: Fluorescein staining measurements
Number of subjects: 63
Study 34137177 — intervention group
Group type: COMPARATOR
Intervention: Lissamine green staining measurements
Number of subjects: 63
Study 34137177 — intervention group
Group type: COMPARATOR
Intervention: Questionnaire scores
Number of subjects: 63
Study 33274479 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA plus steroids
Number of subjects: 209
Study 33274479 — intervention group
Group type: COMPARATOR
Intervention: Steroids alone
Number of subjects: 209
Study 32731786 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 50
Study 32116827 — intervention group
Group type: EXPERIMENTAL
Intervention: EMDR therapy
Number of subjects: 80
Study 32116827 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 80
Study 36566174 — intervention group
Group type: EXPERIMENTAL
Intervention: vilobelimab plus best supportive care (BSC)
Number of subjects: 17
Study 36566174 — intervention group
Group type: COMPARATOR
Intervention: BSC only
Number of subjects: 17
Study 36566174 — intervention group
Group type: EXPERIMENTAL
Intervention: vilobelimab plus BSC
Number of subjects: 17
Study 34629379 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromfenac sodium hydrate 0.1% (NSAID group) applied twice a day
Number of subjects: 125
Study 34629379 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromfenac sodium hydrate 0.1% (NSAID group)
Number of subjects: 125
Study 32189108 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 0
Study 32189108 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32189108 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab (during open-label extension)
Number of subjects: 0
Study 35070287 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein supplements (20 g of protein daily)
Number of subjects: 48
Study 35070287 — intervention group
Group type: COMPARATOR
Intervention: Placebo (zero protein supplements)
Number of subjects: 48
Study 33706847 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdiagnostic seminars combined with high-intensity CBT (TDS+CBT)
Number of subjects: 106
Study 33706847 — intervention group
Group type: COMPARATOR
Intervention: High-intensity cognitive behavioural therapy (CBT) only
Number of subjects: 106
Study 35150804 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-based handrub (ABHR)
Number of subjects: 33
Study 35150804 — intervention group
Group type: COMPARATOR
Intervention: Handscrubbing with PVP-I
Number of subjects: 33
Study 35150804 — intervention group
Group type: COMPARATOR
Intervention: Handscrubbing with CHX
Number of subjects: 33
Study 34071718 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus gasseri OLL2716 (LG21 strain) yogurt for 12 weeks
Number of subjects: 28
Study 34071718 — intervention group
Group type: COMPARATOR
Intervention: Placebo yogurt (LG21 strain-free) for 12 weeks
Number of subjects: 28
Study 34052386 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative oral pregabalin (Lyrica, twice daily starting the evening before surgery, for a total of 4 doses)
Number of subjects: 59
Study 34052386 — intervention group
Group type: COMPARATOR
Intervention: Single‐shot interscalene brachial plexus block (ISBPB, 20 ml of bupivacaine 0.25%)
Number of subjects: 59
Study 34052386 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative oral pregabalin
Number of subjects: 59
Study 34052386 — intervention group
Group type: COMPARATOR
Intervention: Single‐shot interscalene brachial plexus block (ISBPB)
Number of subjects: 59
Study 32811236 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 cycles of neoadjuvant chemotherapy (NACT)
Number of subjects: 30
Study 32811236 — intervention group
Group type: COMPARATOR
Intervention: 3 cycles of neoadjuvant chemotherapy (NACT)
Number of subjects: 30
Study 34994480 — intervention group
Group type: EXPERIMENTAL
Intervention: Florfenicol
Number of subjects: 130
Study 34994480 — intervention group
Group type: COMPARATOR
Intervention: Oxytetracycline
Number of subjects: 130
Study 32930131 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous hyper-fractionated accelerated radiotherapy week-end less (CHARTWEL) - 58.5 Gy/39 fractions/2.5 weeks
Number of subjects: 60
Study 32930131 — intervention group
Group type: COMPARATOR
Intervention: Conventional concurrent chemo-radiotherapy (CCRT) - 66 Gy/33 fractions/6.5 weeks
Number of subjects: 60
Study 32930131 — intervention group
Group type: EXPERIMENTAL
Intervention: CHARTWEL
Number of subjects: 60
Study 32930131 — intervention group
Group type: COMPARATOR
Intervention: CCRT
Number of subjects: 60
Study 35938258 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa/carbidopa 100/25 mg three times per day for 80 weeks (early-start)
Number of subjects: 445
Study 35938258 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 40 weeks followed by levodopa/carbidopa 100/25 mg three times per day for 40 weeks (delayed-start)
Number of subjects: 445
Study 35938258 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-start treatment
Number of subjects: 445
Study 35938258 — intervention group
Group type: COMPARATOR
Intervention: Delayed-start treatment
Number of subjects: 445
Study 33992441 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant administration of CYD‐TDV and bivalent HPV vaccine
Number of subjects: 478
Study 33992441 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential administration of CYD‐TDV and bivalent HPV vaccine
Number of subjects: 478
Study 32594370 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose RTX (Protocol 1, one dose of RTX 375 mg/m2)
Number of subjects: 42
Study 32594370 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard RTX protocol (Protocol 2, four weekly doses of rituximab 375 mg/m2)
Number of subjects: 42
Study 32594370 — intervention group
Group type: COMPARATOR
Intervention: Ponticelli’s regimen (Control)
Number of subjects: 42
Study 32594370 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of all groups
Number of subjects: 42
Study 34936819 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient messages from cases (patients who died by suicide, were hospitalized, or presented to the ED)
Number of subjects: 149
Study 34936819 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient messages from cases
Number of subjects: 149
Study 34936819 — intervention group
Group type: COMPARATOR
Intervention: Control group (randomly selected group)
Number of subjects: 149
Study 34936819 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 149
Study 33621109 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide oral 15 mg/d, days 1‐14/21 plus standard R‐CHOP21
Number of subjects: 570
Study 33621109 — intervention group
Group type: COMPARATOR
Intervention: Placebo/R‐CHOP21
Number of subjects: 570
Study 33341114 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention components (educational components of the multifaceted implementation program)
Number of subjects: 0
Study 33341114 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper-based components of the intervention
Number of subjects: 0
Study 33341114 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital components of the intervention
Number of subjects: 0
Study 33341114 — intervention group
Group type: EXPERIMENTAL
Intervention: One-time outreach visit
Number of subjects: 0
Study 33341114 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational components for patients
Number of subjects: 0
Study 32192317 — intervention group
Group type: EXPERIMENTAL
Intervention: SmartVest
Number of subjects: 60
Study 32192317 — intervention group
Group type: EXPERIMENTAL
Intervention: RespIn 11
Number of subjects: 60
Study 32192317 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological therapy alone
Number of subjects: 60
Study 34706682 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-care counseling
Number of subjects: 54
Study 34706682 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 54
Study 35346499 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin-Cinnamon
Number of subjects: 122
Study 35346499 — intervention group
Group type: COMPARATOR
Intervention: Aspirin-Placebo
Number of subjects: 122
Study 616689230 — intervention group
Group type: EXPERIMENTAL
Intervention: Flap anchoring with suction drains (Group A)
Number of subjects: 200
Study 616689230 — intervention group
Group type: COMPARATOR
Intervention: Suction drains alone (Group B)
Number of subjects: 200
Study 33079009 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Number of subjects: 236
Study 33079009 — intervention group
Group type: COMPARATOR
Intervention: Monopolar electrocautery
Number of subjects: 236
Study 32532267 — intervention group
Group type: EXPERIMENTAL
Intervention: nano-carbonate apatite dentifrice
Number of subjects: 48
Study 32532267 — intervention group
Group type: COMPARATOR
Intervention: control dentifrice
Number of subjects: 48
Study 33651438 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP‐1RA exenatide once‐weekly (ExQW) for 36 weeks
Number of subjects: 42
Study 33651438 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 36 weeks
Number of subjects: 42
Study 34148388 — intervention group
Group type: EXPERIMENTAL
Intervention: Scale ultrasound
Number of subjects: 76
Study 34148388 — intervention group
Group type: COMPARATOR
Intervention: Traditional ultrasound
Number of subjects: 76
Study 33436031 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment strategies involving research nurse involvement and engagement of clinical colleagues.
Number of subjects: 19
Study 33436031 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative research techniques to explore recruitment issues.
Number of subjects: 19
Study 33436031 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear presentation of medical and surgical treatment options.
Number of subjects: 19
Study 33436031 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-trial training for recruiters.
Number of subjects: 19
Study 33436031 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-clinician relationships.
Number of subjects: 19
Study 34756787 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxadustat treatment for 12 weeks
Number of subjects: 55
Study 34756787 — intervention group
Group type: COMPARATOR
Intervention: Post-12 weeks follow-up
Number of subjects: 55
Study 33771368 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic-guided TAP block (LAP-arm)
Number of subjects: 50
Study 33771368 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-guided TAP block (US-arm)
Number of subjects: 50
Study 36246128 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) for 12 weeks, 40–60 min, 3 days a week
Number of subjects: 23
Study 36246128 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 23
Study 36246128 — intervention group
Group type: EXPERIMENTAL
Intervention: Detraining for 30 days after HIIT
Number of subjects: 23
Study 33158422 — intervention group
Group type: EXPERIMENTAL
Intervention: EfiKroniK group (physical exercise programme tailored to each patient)
Number of subjects: 370
Study 33158422 — intervention group
Group type: COMPARATOR
Intervention: Standard healthy life prescription (PVS)
Number of subjects: 370
Study 33158422 — intervention group
Group type: EXPERIMENTAL
Intervention: EfiKroniK group
Number of subjects: 370
Study 34293955 — intervention group
Group type: EXPERIMENTAL
Intervention: Active phase with smart insulin pen cap (alarms/reminders)
Number of subjects: 80
Study 34293955 — intervention group
Group type: COMPARATOR
Intervention: Control phase (masked phase without feedback)
Number of subjects: 80
Study 33647225 — intervention group
Group type: EXPERIMENTAL
Intervention: Awake prone positioning
Number of subjects: 0
Study 33647225 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33378425 — intervention group
Group type: COMPARATOR
Intervention: Er,Cr:YSGG laser followed by CPP‐ACP
Number of subjects: 80
Study 33378425 — intervention group
Group type: COMPARATOR
Intervention: CPP‐ACP
Number of subjects: 80
Study 33378425 — intervention group
Group type: COMPARATOR
Intervention: Er,Cr:YSGG laser
Number of subjects: 80
Study 33378425 — intervention group
Group type: COMPARATOR
Intervention: Control group, no preventive measures
Number of subjects: 80
Study 35236652 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab combined with chemotherapy
Number of subjects: 100
Study 35236652 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (Control)
Number of subjects: 100
Study 32737670 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based treatment targeting emotion regulation problems over 16 weeks
Number of subjects: 37
Study 32847924 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV vaccination story
Number of subjects: 64
Study 32847924 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐cigarette story
Number of subjects: 64
Study 32847924 — intervention group
Group type: EXPERIMENTAL
Intervention: General heuristics
Number of subjects: 64
Study 32847924 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of statistics and links to scientific research
Number of subjects: 64
Study 32847924 — intervention group
Group type: EXPERIMENTAL
Intervention: Feelings about news media
Number of subjects: 64
Study 33742222 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstring tendon reconstruction
Number of subjects: 51
Study 33742222 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadriceps tendon reconstruction
Number of subjects: 51
Study 33523233 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab and nab-Paclitaxel (A+nP)
Number of subjects: 902
Study 33523233 — intervention group
Group type: COMPARATOR
Intervention: Placebo and nab-Paclitaxel (P+nP)
Number of subjects: 902
Study 32394851 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril, indapamide SR, and metformin (n=40)
Number of subjects: 120
Study 32394851 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril, moxonidin, and metformin (n=40)
Number of subjects: 120
Study 32394851 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril, indapamide SR, and amlodipine (n=40)
Number of subjects: 120
Study 34020072 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime-avibactam (CAZ-AVI)
Number of subjects: 90
Study 32204134 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaching intervention (face-to-face combined with telephone)
Number of subjects: 0
Study 32204134 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 36375331 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive Training (MCT)
Number of subjects: 126
Study 36375331 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducational intervention
Number of subjects: 126
Study 33186620 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial Breast Irradiation (PBI)
Number of subjects: 258
Study 33186620 — intervention group
Group type: COMPARATOR
Intervention: Whole Breast Irradiation (WBI)
Number of subjects: 258
Study 35343796 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic group (Bifidobacterium lactis Probio-M8, atorvastatin, metoprolol)
Number of subjects: 60
Study 35343796 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (placebo, atorvastatin, metoprolol)
Number of subjects: 60
Study 34670321 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated fetal tachycardia (FHR ≥160 bpm for at least 10 minutes)
Number of subjects: 728
Study 34670321 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal tachycardia
Number of subjects: 728
Study 35228291 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic anticoagulation (rivaroxaban 10 mg once a day for 3 months)
Number of subjects: 4
Study 35228291 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic anticoagulation (rivaroxaban 20 mg once a day for 3 months)
Number of subjects: 4
Study 36457273 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib plus pembrolizumab
Number of subjects: 73
Study 36457273 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 73
Study 33839979 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative Adjuvant Transarterial Infusion Chemotherapy with FOLFOX
Number of subjects: 0
Study 33792511 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychodrama (8 sessions during hospitalization)
Number of subjects: 16
Study 33792511 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting for treatment)
Number of subjects: 16
Study 34719399 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium oxide monohydrate (MOMH) 226 mg, once daily at bedtime for 60 days
Number of subjects: 216
Study 34719399 — intervention group
Group type: COMPARATOR
Intervention: Placebo, once daily at bedtime for 60 days
Number of subjects: 216
Study 32992991 — intervention group
Group type: EXPERIMENTAL
Intervention: MmPylRS variants dedicated to tryptophan and tyrosine analogs
Number of subjects: 0
Study 32992991 — intervention group
Group type: EXPERIMENTAL
Intervention: MmPylRS variants with systematic mutagenesis
Number of subjects: 0
Study 33353864 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal Patient Profile‐Prostate (P3P)
Number of subjects: 392
Study 33353864 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 392